Abstract
The Hedgehog inhibitors are promising alternative for patients with advanced basal cell carcinoma that are not amenable to radiotherapy or surgery. Sonidegib, also known as LDE225, is an orally available SMO antagonist that was recently approved by the US FDA for the treatment of patients with locally advanced basal cell carcinoma. This article will provide an overview of the pharmacology and pharmacokinetics of sonidegib and in-depth analysis of the BOLT trial with additional data from the 12-month update. The present challenges associated with Hedgehog inhibitors will also be discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2095-2105 |
| Number of pages | 11 |
| Journal | Future Oncology |
| Volume | 12 |
| Issue number | 18 |
| DOIs | |
| State | Published - Sep 2016 |
Keywords
- BOLT trial
- basal cell carcinoma
- sonidegib
ASJC Scopus subject areas
- Oncology
- Cancer Research